A journey toward Pharmaceutical Innovation

1998: Company formed with start up funds from Novartis, Pfizer, J&J and GSK

1999: First mention of AMS Microdosing in scientific literature by Xceleron

1999: Xceleron Ltd is certified GLP compliant by UK MHRA

1999: First drug on market using AMS data for regulatory Mass Balance 

2000: Industry validation study (AMS vs LSC) published with Pfizer, GSK, Novartis and J&J

2001: First Human Mass Balance/Metabolite Profiling study published with Janssen Pharmaceutica

2002: Name changed from CBAMS to Xceleron

2003: Presentation given to the EMEA Safety Working Party on Microdosing

2004: Presentation given to the US FDA Critical Path Group resulting in inclusion of Microdosing

2006: CREAM - 5 compound Microdose trial results published

2007: Start of EUMAPP - 7 compound microdose to pharmacologic dose trial

2008: Xceleron Ltd passed first GCP inspection

2008: Xceleron Inc opens in Maryland, USA

2009: Xceleron launches solution to FDA 'MIST' Guidance